June 13, 2024 / Care

Cranbury Pharmaceuticals (Tris Pharma) Receives FDA Approval for First Generic Version of Emflaza® (deflazacort) for Duchenne

Cranbury Pharmaceuticals, a subsidiary of Tris Pharma, today announced the U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne. The generic deflazacort oral suspension, a corticosteroid indicated to treat Duchenne in patients five years of age and older, is now available to patients in the U.S.

If you have questions about accessing Cranbury’s generic deflazacort oral suspension, please reach out to the company’s patient assistance program, Cranbury Connects, by visiting https://www.cranburypharma.com/cranbury-connects/. You can also find helpful information on PPMD’s Access & Coverage Resources page.

Patient assistance representatives from Tris will also be participating in PPMD’s 30th Annual Conference Patient Assistance Programs 1:1 sessions. During these meetings, representatives from multiple patient assistance programs will be available to provide information on how companies might help families with understanding access to and payment for approved treatments and therapies.

What Does This Mean For My Child?

If you or your child is currently on Emflaza, please talk with your neuromuscular provider and insurance about how the availability of generic deflazacort may impact your medication access and policy coverage. 

Navigating Steroid Choices

PPMD’s Navigating Steroid Choices webinar features a conversation about decision making regarding steroids with members of the University of Iowa team. The discussion covers considerations for initiating a new steroid drug and/or regimen, differences and similarities of brand versus generic medication, and the different processes for obtaining access to these medications. 

Watch the Recording

FAQ: Choosing a Steroid Drug, Dose, and Regimen

PPMD’s Care team has put together an FAQ resource providing important information about considerations in steroid decision making, starting a new medication, and what you need to know about brand name versus generic drugs.

Access the FAQ

Join Our Mailing List